Heinrich MC - Search Results

1

Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia.

Goemans BF, Zwaan CM, Miller M, Zimmermann M, Harlow A, Meshinchi S, Loonen AH, Hählen K, Reinhardt D, Creutzig U, Kaspers GJ, Heinrich MC. Goemans BF, et al. Among authors: heinrich mc. Leukemia. 2005 Sep;19(9):1536-42. doi: 10.1038/sj.leu.2403870. Leukemia. 2005. PMID: 16015387

2

Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies.

Heinrich MC, Blanke CD, Druker BJ, Corless CL. Heinrich MC, et al. J Clin Oncol. 2002 Mar 15;20(6):1692-703. doi: 10.1200/JCO.2002.20.6.1692. J Clin Oncol. 2002. PMID: 11896121 Review.

3

KIT mutations are common in testicular seminomas.

Kemmer K, Corless CL, Fletcher JA, McGreevey L, Haley A, Griffith D, Cummings OW, Wait C, Town A, Heinrich MC. Kemmer K, et al. Among authors: heinrich mc. Am J Pathol. 2004 Jan;164(1):305-13. doi: 10.1016/S0002-9440(10)63120-3. Am J Pathol. 2004. PMID: 14695343 Free PMC article.

4

High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib.

Al-Ali HK, Heinrich MC, Lange T, Krahl R, Mueller M, Müller C, Niederwieser D, Druker BJ, Deininger MW. Al-Ali HK, et al. Among authors: heinrich mc. Hematol J. 2004;5(1):55-60. doi: 10.1038/sj.thj.6200319. Hematol J. 2004. PMID: 14745431

5

Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography.

Deininger MW, McGreevey L, Willis S, Bainbridge TM, Druker BJ, Heinrich MC. Deininger MW, et al. Among authors: heinrich mc. Leukemia. 2004 Apr;18(4):864-71. doi: 10.1038/sj.leu.2403307. Leukemia. 2004. PMID: 14973502

6

Targeting FLT3 kinase in acute myelogenous leukemia: progress, perils, and prospects.

Heinrich MC. Heinrich MC. Mini Rev Med Chem. 2004 Mar;4(3):255-71. doi: 10.2174/1389557043487394. Mini Rev Med Chem. 2004. PMID: 15032673 Review.

7

In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: identification of T-cell ALL and FAB M5 AML as the most sensitive subsets.

Goemans BF, Zwaan CM, Harlow A, Loonen AH, Gibson BE, Hählen K, Reinhardt D, Creutzig U, Heinrich MC, Kaspers GJ. Goemans BF, et al. Among authors: heinrich mc. Blood. 2005 Nov 15;106(10):3532-7. doi: 10.1182/blood-2005-04-1640. Epub 2005 Jul 28. Blood. 2005. PMID: 16051737 Free article.

8

Differences in the prevalence of PTPN11 mutations in FAB M5 paediatric acute myeloid leukaemia.

Goemans BF, Zwaan CM, Martinelli S, Harrell P, de Lange D, Carta C, Reinhardt D, Hählen K, Creutzig U, Tartaglia M, Heinrich MC, Kaspers GJ. Goemans BF, et al. Among authors: heinrich mc. Br J Haematol. 2005 Sep;130(5):801-3. doi: 10.1111/j.1365-2141.2005.05685.x. Br J Haematol. 2005. PMID: 16115145 Free article. No abstract available.

9

Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.

Schittenhelm MM, Shiraga S, Schroeder A, Corbin AS, Griffith D, Lee FY, Bokemeyer C, Deininger MW, Druker BJ, Heinrich MC. Schittenhelm MM, et al. Among authors: heinrich mc. Cancer Res. 2006 Jan 1;66(1):473-81. doi: 10.1158/0008-5472.CAN-05-2050. Cancer Res. 2006. PMID: 16397263

10

Phosphoproteomic analysis of AML cell lines identifies leukemic oncogenes.

Walters DK, Goss VL, Stoffregen EP, Gu TL, Lee K, Nardone J, McGreevey L, Heinrich MC, Deininger MW, Polakiewicz R, Druker BJ. Walters DK, et al. Among authors: heinrich mc. Leuk Res. 2006 Sep;30(9):1097-104. doi: 10.1016/j.leukres.2006.01.001. Epub 2006 Feb 7. Leuk Res. 2006. PMID: 16464493

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

282 results

Search Page